Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators.
about
Asenapine for bipolar disorderSystematic assessment of environmental risk factors for bipolar disorder: an umbrella review of systematic reviews and meta-analyses.The Prevalence of Metabolic Syndrome in Alcohol Use Disorders: A Systematic Review and Meta-analysis.Neurocognitive functioning in overweight and obese patients with bipolar disorder: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM)Cardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial.Bipolar disorder in primary care: clinical characteristics of 740 primary care patients with bipolar disorder.Lovastatin as an adjuvant to lithium for treating manic phase of bipolar disorder: a 4-week, randomized, double-blind, placebo-controlled clinical trialMetabolic syndrome and childhood trauma: Also comorbidity and complication in mood disorderIntegrated neurobiology of bipolar disorder.Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables.LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDYEvidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for PsychopharmacologyAltered activation of innate immunity associates with white matter volume and diffusion in first-episode psychosis.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.DNA methylation, insulin resistance and second-generation antipsychotics in bipolar disorder.Use of an electronic metabolic monitoring form in a mental health service - a retrospective file audit.Physical activity preferences of individuals diagnosed with schizophrenia or bipolar disorderRisk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysisMetabolic syndrome and adverse clinical outcomes in patients with bipolar disorder.Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder.Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical RecordThe DRD3 Ser9Gly Polymorphism Predicted Metabolic Change in Drug-Naive Patients With Bipolar II Disorder.The prevalence of bipolar disorder in general primary care samples: a systematic review.Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis.Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis.Recognition of bipolar disorder type I before the first manic episode: challenges and developments.Metabolic syndrome and major depression.Public health significance of bipolar disorder: implications for early intervention and prevention.Diabetes mellitus and severe mental illness: mechanisms and clinical implications.Genomic medicine and risk prediction across the disease spectrum.Psychotherapy Alone and Combined With Medication as Treatments for Bipolar II Depression: A Randomized Controlled Trial.Are medical comorbid conditions of bipolar disorder due to immune dysfunction?Lurasidone: a new treatment option for bipolar depression-a reviewAssociation between history of psychosis and cardiovascular disease in bipolar disorder.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Circadian Clocks as Modulators of Metabolic Comorbidity in Psychiatric Disorders.Physical Exercise for Treatment of Mood Disorders: A Critical Review.The development of lurasidone for bipolar depression.Impact of a nurse practitioner role on metabolic monitoring completion and referrals for consumers admitted to the intensive care area of an acute inpatient psychiatric unit.Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application.
P2860
Q26775399-DAD5EE79-4989-4A6D-AABB-3D14C7C5A8F5Q30234571-B4851A81-8757-4F2B-88F7-E72CEAEE8EC8Q30249403-5E17C2CF-8A6A-433E-B488-759BCC39C9D7Q30897232-92481B2D-9552-4476-8E02-B97C1FF4D7B0Q30949176-87C9824B-F588-4499-98C4-E53FCBD70720Q33992243-EBFAE68E-87B4-4018-84D6-C146E6C3FC89Q34009409-71B8C7A9-8D25-4490-9A94-64E9B74F70E6Q34047592-1FEBBE67-7557-417B-99C9-CE0911CB49F3Q34080310-7BD13415-F31C-4A9F-AC5D-3F0F31D52E2DQ34386877-4316C9C6-8341-46D7-82AE-973F1B62763DQ34515834-24DD05AE-D2C6-4182-A3FE-4ABF11F8B720Q34676317-F9305490-BAA3-4A26-BCFC-447550CB06B1Q35603078-AF4BFF03-EF33-4159-AA9B-DECC0A6216A7Q35754726-CCCC792F-EFD5-49A0-A8E4-502AF5486893Q35848001-A15A9BC9-63E2-4ABC-B2E2-6375B1C480F9Q35994346-880C731F-FD47-426B-B2A0-4803882DCEADQ36074188-0A221151-F9A8-4168-A87E-4E2300A49686Q36118736-B455BCA2-0F0A-44BE-9909-76292C8C9E3FQ36225626-029DF56F-5746-4EE8-8425-418385F9A83CQ36834290-22FC5F04-E349-48E0-A2C8-EF3353E28CA4Q36921831-E9926CAC-9A1C-4A22-B85C-73640306EA5AQ37205535-BA1AA9C4-1603-4473-B518-DCDD009B33EEQ37424574-9B9CE399-F5D7-44FC-A8E3-7A1FA9F4DFABQ37514635-2980EA2D-7CAE-4617-BD09-4FCBE4E27C9BQ37635208-63201F8B-E9C4-4EAB-935E-03C845238A7EQ38125216-61602140-4530-478B-97BA-8CC00CF373F6Q38150605-08C4928D-3783-45FD-9BC9-8B73D0F15149Q38152793-D1A3AFE9-EE42-4B48-92BC-3957948F45E3Q38274901-6014EDAE-236E-4257-8BE3-7DC853E28FA7Q38322338-8303245E-C270-49EA-A2B1-B607A734510EQ38374033-F9A2049C-D0D8-4936-BAE4-51301E67259DQ38378743-253D9FB5-C514-4ADE-BA87-451AD7EA4DBCQ38411188-7A7429F5-C5E4-4282-864D-D9827B54AD57Q38524175-428D6256-05AA-41B1-8EA6-0B8D61422D95Q38546598-F38A10EC-4DCF-43EE-A22A-EB9027D0E6FDQ38611693-400B8E57-ED28-4EE8-B80D-1BFC62364991Q38684018-28A8C67F-49CC-46C8-B2CC-4C76D195B295Q38697937-40FE4D70-A5EE-45DB-B6AC-D78D2328DC29Q38904115-D163CA81-FBBD-4523-BBE3-FDB9A9DA7F83Q39077270-9B47E769-9948-4140-9CED-E0EC9E3DA96D
P2860
Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Metabolic syndrome and metabol ...... evalence rates and moderators.
@ast
Metabolic syndrome and metabol ...... evalence rates and moderators.
@en
Metabolic syndrome and metabol ...... evalence rates and moderators.
@nl
type
label
Metabolic syndrome and metabol ...... evalence rates and moderators.
@ast
Metabolic syndrome and metabol ...... evalence rates and moderators.
@en
Metabolic syndrome and metabol ...... evalence rates and moderators.
@nl
prefLabel
Metabolic syndrome and metabol ...... evalence rates and moderators.
@ast
Metabolic syndrome and metabol ...... evalence rates and moderators.
@en
Metabolic syndrome and metabol ...... evalence rates and moderators.
@nl
P2093
P50
P921
P1476
Metabolic syndrome and metabol ...... evalence rates and moderators.
@en
P2093
Amber De Herdt
Christoph U Correll
Kristof Vansteelandt
Marc De Hert
Pascal Sienaert
P304
P356
10.1176/APPI.AJP.2012.12050620
P407
P577
2013-03-01T00:00:00Z